Rafael Holdings, Inc. (NYSE: RFL)

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in companies that develop pharmaceuticals and medical devices.

The company’s primary focus is the advancement of Trappsol® Cyclo™ for the potential treatment of Niemann Pick disease type C1 a rare fatal genetic disorder.

In addition the company holds a majority interest in LipoMedix which is developing a liposome based cancer therapy.

It also holds interests in Barer a cancer research entity Rafael Medical Devices which creates orthopedic surgical instruments Cornerstone which works on cancer metabolism based therapeutics and Day Three which provides technology to increase bioavailability of third party products.

The company retains a small real estate holding consisting of a portion of a commercial building in Jerusalem Israel.

The company generates revenue primarily from leasing its real estate property in Jerusalem and from licensing agreements and research collaborations with its portfolio companies.

While the pharmaceutical and medical device products remain in development the company does not yet receive significant product sales.

Future revenue will depend on the successful commercialization of Trappsol® Cyclo™ the VECTR System and other pipeline candidates upon regulatory approval and market acceptance.

The company operates through the following segments:

• Pharmaceuticals: This segment includes the development of Trappsol® Cyclo™ for Niemann Pick disease type C1 and the advancement of LipoMedix’s Promitil® as a liposome based cancer therapy as well as early stage research conducted through Barer.

• Medical Devices: This segment consists of Rafael Medical Devices which designs and commercializes the VECTR System a cleared orthopedic instrument for minimally invasive ligament or fascia release surgeries.

• Real Estate: This segment comprises the ownership of a portion of a commercial building in Jerusalem Israel that is leased to tenants generating rental income.

The company holds a niche position in the biotechnology sector focusing on rare diseases and oncology through proprietary drug candidates that have received orphan drug designations and fast track status from regulatory agencies.

Its medical device business benefits from an FDA clearance that allows immediate market entry for the VECTR System.

Competitors include larger pharmaceutical firms with greater resources but the company leverages its targeted pipeline and strategic partnerships to differentiate itself.

The company serves patients suffering from rare genetic disorders and oncology patients seeking new therapeutic options.

Its medical device customers are hospitals ambulatory surgery centers and orthopedic clinics that perform ligament release procedures.

The real estate segment generates income from commercial tenants occupying the building in Jerusalem.